Characterization of MPL-nanoliposomes with Her2/neu derived peptide GP2 as vaccine against breast cancer in BALB/c mice TUBO xenograft model

HER2/neu is an immunogenic protein eliciting both humoral and cellular immune responses in patients with HER2/neu-positive tumors. The goal of this study was to induce and enhance an effective cytotoxic T lymphocyte (CTL) response against peptide Gp2 derived from HER 2/neu oncogene and MPL adjuvant by employing the potential benefit of liposomes as a co-delivery vehicle. MPL have been shown to have potent adjuvant activity for a wide range of antigens. In this study, different groups of mice were subcutaneously vaccinated with five formulations containing DMPC/DMPG/Chol (30:4:6) with or without DOPE, MPL (25 µg per mouse) and peptide conjugated to - DSPE- mPEG2000- Maleimide lipid and also Hepes/sucrose buffer as control. Released amount of IFN-γ were determined by flow cytometric analysis, ELISpot kits, Intracellular cytokine assay and RT-PCR was used to identify IFN-γ and IL-4 producing cells. Consequently, mice immunized with lip-DOPE-MPL-GP2 formulation had the most released IFN-γ and the highest CTL responses followed by Lip-Gp2 and GP2 formulation group

Characterization of MPL-nanoliposomes with Her2/neu derived peptide GP2 as vaccine against breast cancer in BALB/c mice TUBO xenograft model Keywords:

HER2/neu , GP2 peptide , antigen-specific immunity , cytotoxic T lymphocyte , MPL ,